The Sunburst Sign in the Mesentery: Unveiling the Diagnosis With ⁶⁸Ga DOTATATE PET/CT.

Clin Nucl MedApr 3, 2026 (epub)
Case ReportGastroenterologyOncology (Medical)

Ömer F Şahin, Dilruba Şahin, Zehranur Tosunoğlu

✦ AI-curated · Sources linked

Case in brief

A 57-year-old man with abdominal pain and diarrhea had a spiculated, calcified mesenteric mass on contrast-enhanced CT, initially considered a desmoid tumor. The mass was ametabolic on ¹⁸F-FDG PET/CT, supporting that impression. In contrast, ⁶⁸Ga DOTATATE PET/CT showed intense uptake in the mass and an ileal focus. Histopathology established an ileal neuroendocrine tumor with mesenteric lymph node metastasis.

What made this case unusual

The mesenteric mass had a “sunburst” calcification pattern and was FDG-negative, yet showed intense ⁶⁸Ga DOTATATE uptake alongside the primary ileal focus.

Diagnostic / clinical pearl

Ametabolic ¹⁸F-FDG PET/CT does not exclude an ileal neuroendocrine tumor in a patient with a spiculated mesenteric mass; ⁶⁸Ga DOTATATE PET/CT can help identify the primary focus and assess disease extent.

Source

PubMed · PMID 41955255

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.